Abstract: The invention relates to an on-site medical gas production plant (100) comprising a unit (50) for purifying gas, such as air, a first vessel (A) for storing purified gas, and a main gas line (10) fluidically connecting the gas purification unit (50) to the said first storage vessel (A). It furthermore comprises a three-way solenoid valve (VA) arranged on the main gas line (10) upstream of the first storage vessel (A), and furthermore connected to the atmosphere (at 12) via a vent line (11), as well as an operating device (4) which controls at least the three-way solenoid valve (VA), and at least a first gas analysis device (D1) of which a first measurement line (29) is fluidically connected (at 28) to the main line (10), upstream of the three-way solenoid valve (VA), and which is electrically connected to the said operating device (4).

Abstract: The invention relates to a method for operating a plant (100) for on-site production of medical gas, such as air or oxygen, comprising a main gas line (10) comprising, in series, a first vessel (A) for storing gas and a second vessel (B) for storing purified gas, and a secondary line (20) fluidically connected to the main line (10), downstream of the first vessel (A) for storing gas, and comprising a third vessel (C) for storing gas, the main gas line (10) and the secondary line (20) each supplying at least one gas consumer site (30), in particular a network of pipes in a hospital.

Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).

Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).

Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).

Abstract: The invention relates to xenon or xenon-containing gases which is/are used for producing an adjuvant that is administered together with another medicament, such as an antiviral, antibacterial, antimycotic, neuroprotective, or anticancerogenic agent, a parasympathomimetic, parasympatholytic, spasmolytic, symnpathomimetic, sympatholytic, preceptor blocker, tranquilizer, neuroleptic, antidepressant, analgesic, antipyretic, anticephalalgic, anti-Parkinson's drug, analeptic, antiepileptic, antiemetic, emetic, a substance influencing coagulation, an amino acid, a vitamin, or a hormone.

Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).

Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as spasmolytic. The spasmolytic is preferably a medicament for the treatment of vasospasms, in particular for the treatment of cerebral vasospasms or coronary vasospasms.

Abstract: An anesthesia system has ventilation gas supply flow structure for supplying ventilation gas to a patient. Structure is provided for the exhaled gas and for recycling the anesthetic gas-containing gas. The system uses a mass spectrometer connected to these flow structures to measure the content of at least one gas component in the gases and to control the flow through at least one of the flow structures in accordance with at least one measured value of the gas content.

Abstract: A process is disclosed for separating a component from a gaseous mixture, in particular for separating xenon from the breathing gas exhaled by an anaesthetized patient. The disclosed process has the following steps: the gaseous mixture is brought into contact with a cooling surface at a temperature below the melting point of the components to be separated, the proportion of the gaseous mixture which is not condensed on the cooling surface in a solid state is carried away, and the component condensed on the cooling surface is heated above the melting point of the component to be separated. Also disclosed are a device for carrying out this process, a corresponding process for recovering anaesthetic gas and an associated anaesthetic equipment.